African clinical trial denied access to key COVID drug Paxlovid

Heidi Ledford and Amy Maxmen

Nature, 2022, vol. 604, issue 7906, 412-413

Abstract: Supply shortages and limits on research leave low- and middle-income countries struggling to access Pfizer’s COVID-19 antiviral.

Keywords: Public health; Medical research; Intellectual-property rights; SARS-CoV-2 (search for similar items in EconPapers)
Date: 2022
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/d41586-022-00919-5 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:604:y:2022:i:7906:d:10.1038_d41586-022-00919-5

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/d41586-022-00919-5

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().